Curt Labelle
Global health private equity
United States
Education
Work Experience
Managing Partner
2022
Investments in companies developing therapeutics and diagnostics with attractive financial upside and the potential to address healthcare needs globally. Focus on late clinical and early commercial stage companies with target deployment of ~$30m per company.
Advisor
2020
Our team recommends and manages healthcare investments for the AXA IM Prime Impact Fund. We invest in therapeutic and diagnostic companies that can improve health globally and generate strong financial returns. Investments include Alydia Health (acquired by Organon), Z Optics, Revelation Bio, Eyenuk, Ophirex and Biolinq.
2024
Board Member
2024
Novocuff is a clinical stage company developing solutions for premature labor
Board Member
2023
2022
Board Member
2022
Epion is a late-stage clinical company developing novel treatments for keratoconus
Board Member
2022
MNHI is developing solutions to make labor and delivery safer for mothers and babies.
2022
Board Member
2022
Solutions for snakebites
2020
Chair Of The Board Of Directors
2020
Intraocular lens aiming to offer accurate vision from near to far.
2015
Member, Board of Directors
2015
Developing novel therapy for River Blindness. Sold Priority Review Voucher.
2017 - 2023
Chair, Steering Committee
2017 - 2023
Collaboration with the Serum Institute of India to develop high quality anti-venoms for the developing world, and novel treatments for tuberculosis and bladder cancer.